ask1 inhibitor Search Results


inhibitor of ask1 (thioredoxin)  (Merck KGaA)
90
Merck KGaA inhibitor of ask1 (thioredoxin)
Inhibitor Of Ask1 (Thioredoxin), supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pmc03823298-27-1-7?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
inhibitor of ask1 (thioredoxin) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ask1 inhibitor nqdi-1  (Axon Medchem LLC)
90
Axon Medchem LLC ask1 inhibitor nqdi-1
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Ask1 Inhibitor Nqdi 1, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pmc06327059-308-17-20?v=Axon+Medchem+LLC
Average 90 stars, based on 1 article reviews
ask1 inhibitor nqdi-1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ask1 inhibitor selonsertib  (ApexBio)
90
ApexBio ask1 inhibitor selonsertib
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Ask1 Inhibitor Selonsertib, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pmc11667557-107-79-83?v=ApexBio
Average 90 stars, based on 1 article reviews
ask1 inhibitor selonsertib - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
docking of inhibitors into the atp binding site of ask1 using autodock vina  (AUTODOCK GmbH)
90
AUTODOCK GmbH docking of inhibitors into the atp binding site of ask1 using autodock vina
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Docking Of Inhibitors Into The Atp Binding Site Of Ask1 Using Autodock Vina, supplied by AUTODOCK GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pmc04113037-173-44-53?v=AUTODOCK+GmbH
Average 90 stars, based on 1 article reviews
docking of inhibitors into the atp binding site of ask1 using autodock vina - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
neuroprotective effect by ask1 inhibitor  (Neuroprotect Inc)
90
Neuroprotect Inc neuroprotective effect by ask1 inhibitor
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Neuroprotective Effect By Ask1 Inhibitor, supplied by Neuroprotect Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pm32930624-166-48-44?v=Neuroprotect+Inc
Average 90 stars, based on 1 article reviews
neuroprotective effect by ask1 inhibitor - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
inhibitor of ask1 thioredoxin  (Biomol GmbH)
90
Biomol GmbH inhibitor of ask1 thioredoxin
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Inhibitor Of Ask1 Thioredoxin, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pm25449786-100-13-28?v=Biomol+GmbH
Average 90 stars, based on 1 article reviews
inhibitor of ask1 thioredoxin - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ask1 inhibitors  (PharmaDesign Inc)
90
PharmaDesign Inc ask1 inhibitors
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Ask1 Inhibitors, supplied by PharmaDesign Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pm21134755-3-17-54?v=PharmaDesign+Inc
Average 90 stars, based on 1 article reviews
ask1 inhibitors - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ask1 pharmacological inhibitor selonsertib  (MedKoo Inc)
90
MedKoo Inc ask1 pharmacological inhibitor selonsertib
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Ask1 Pharmacological Inhibitor Selonsertib, supplied by MedKoo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pm40189195-63-14-15?v=MedKoo+Inc
Average 90 stars, based on 1 article reviews
ask1 pharmacological inhibitor selonsertib - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ask1 inhibitors  (LakePharma)
90
LakePharma ask1 inhibitors
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Ask1 Inhibitors, supplied by LakePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pm37883895-253-10-16?v=LakePharma
Average 90 stars, based on 1 article reviews
ask1 inhibitors - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ask1 inhibitors  (Informa UK Limited)
90
Informa UK Limited ask1 inhibitors
BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or <t>ASK1</t> inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data
Ask1 Inhibitors, supplied by Informa UK Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ask1+inhibitor/pm38069610-22-27-2?v=Informa+UK+Limited
Average 90 stars, based on 1 article reviews
ask1 inhibitors - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ask1 inhibitor 10  (MuseChem Chemicals)
N/A
TC ASK 10（Cat No.:R061891）is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), a key component of the MAPK signaling pathway involved in cellular responses to stress, inflammation, and apoptosis. By inhibiting ASK1, TC ASK
   Buy from Supplier
ask1 inhibitor 10  (Cayman Chemical)
N/A
ASK1 INHIBITOR 10
   Buy from Supplier

Image Search Results


BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or ASK1 inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data

Journal: Nature Communications

Article Title: BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity

doi: 10.1038/s41467-018-07927-y

Figure Lengend Snippet: BRCA2 inactivation causes sensitivity to TNFα in cancer cells. a KBM-7 harboring shRNAs targeting BRCA2 were treated with doxycycline for 48 h and subsequently plated and treated with indicated TNFα concentrations for 5 days. b KBM-7-shBRCA2 #1 cells with shRNAs targeting SAM68, TNFR1 or SCR were treated with or without doxycycline and treated with indicated TNFα concentrations for 5 days. c Breast cancer cell lines MDA-MB-231, HCC38 and BT-549 harboring shLUC, shBRCA2 #1 or shBRCA2 #2 were pre-treated for 48 h with doxycycline and subsequently treated with indicated TNFα concentrations for 5 days. d DLD-1 wt or BRCA2 −/− cells were plated and treated for 5 days with indicated TNFα concentrations. e , f BT-549 cells harboring shLUC or shBRCA2 #2 were treated with doxycycline for 48 h and subsequently treated with indicated concentrations of TNFα, in the presence or absence of JNK inhibitor ( e ) or ASK1 inhibitor ( f ) for 5 days. g BT-549 cell lines harboring indicated shRNAs were transfected with indicated siRNAs for 24 h, and were subsequently treated with doxycycline for 48 h. Cells were re-plated and treated with indicated TNFα concentrations for 5 days. Error bars represent s.e.m. of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t -test. * P < 0.05, *** P < 0.001. h BT-549 cells harboring shRNAs targeting BRCA1 or FANCD2 were treated with doxycycline for 48 h, and subsequently plated and treated with indicated TNFα concentrations for 5 days. i MDA-MB-231, HCC38 or BT-549 cells were plated and treated with or without 100 μM HU and indicated TNFα concentrations for 5 days. Throughout the figure, cell viability was assessed by MTT conversion, and error bars indicate s.e.m. of at least three independent experiments with three technical replicates each. Measurements were normalized to untreated cells. P values were calculated using two-tailed Student’s t -test. For P values, see Supplementary Data

Article Snippet: Cells were treated with indicated concentrations of the following agents: Infliximab (Merck, Sharp and Dome), HU (Sigma), ASK1 inhibitor NQDI-1 (Axon Medchem, #2179), JNK inhibitor SP600125 (Selleck Chemicals, #S1460), Pan caspase inhibitor (Z-VAD-FMK, Promega) and/or recombinant TNFα (Thermofisher).

Techniques: Transfection, Two Tailed Test

Schematic model of inflammatory signaling upon BRCA2 inactivation. BRCA2 inactivation (1) leads to micronuclei formation (2) and cGAS/STING-dependent activation of an interferon response (3). This leads to pro-inflammatory cytokines production, and sensitivity to TNFα, in a TNFR/SAM68 (4) and ASK1/JNK-dependent fashion (5)

Journal: Nature Communications

Article Title: BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity

doi: 10.1038/s41467-018-07927-y

Figure Lengend Snippet: Schematic model of inflammatory signaling upon BRCA2 inactivation. BRCA2 inactivation (1) leads to micronuclei formation (2) and cGAS/STING-dependent activation of an interferon response (3). This leads to pro-inflammatory cytokines production, and sensitivity to TNFα, in a TNFR/SAM68 (4) and ASK1/JNK-dependent fashion (5)

Article Snippet: Cells were treated with indicated concentrations of the following agents: Infliximab (Merck, Sharp and Dome), HU (Sigma), ASK1 inhibitor NQDI-1 (Axon Medchem, #2179), JNK inhibitor SP600125 (Selleck Chemicals, #S1460), Pan caspase inhibitor (Z-VAD-FMK, Promega) and/or recombinant TNFα (Thermofisher).

Techniques: Activation Assay